A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)

Rabab Mohamed Gaafar, Veerle F.M. Surmont, Giorgio V. Scagliotti et al. · European Journal of Cancer · 2011

Cited by 120 works. doi:10.1016/j.ejca.2011.06.045

Authors

References